Objective: To assess the yield of staging laparoscopy (SL) in a multicenter randomized trial in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC) who undergo surgery following neoadjuvant treatment. Background: Occult metastases may be detected at exploratory laparotomy, leading to a non-therapeutic laparotomy. Starting such surgical exploration with a SL may prevent this. Methods: This was a prespecified analysis within the multicenter randomized controlled PREOPANC-2 trial which randomized patients with resectable and borderline resectable PDAC to receive neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine. SL was performed in the same surgical session as the intended resection. Primary outcome was yield of SL to prevent a non-therapeutic laparotomy. Results: Among 369 randomized patients, 322 (87.2%) underwent surgical exploration. At surgery, 240 patients (74.5%) underwent SL and 82 (25.5%) underwent laparotomy without SL. Occult metastases were detected in 39/322 patients (12.1%) and was the main reason (90.5%) for aborting surgery without resection. The rate of non-therapeutic laparotomy was lower in the SL group (4.5% vs. 17.1%, P =0.002; NNT 8). Tumor size ≥3 cm and baseline CA19-9 >500 U/ml were independent predictors for occult metastatic disease. Without these factors, occult metastatic disease was present in 2.8% of patients (95%CI: 0.9-8.0), with one of these factors 14.8% (95%CI: 5.9-32.5) and with both 28.9% (95%CI: 17.0-44.8). Conclusions: A SL just prior to surgical exploration in patients with PDAC following neoadjuvant treatment was able to detect occult metastases with a NNT of 8. Tailored use of SL only in patients with one or two risk factors would further lower this NNT.
Rompen et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: